WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? - CRISPR Therapeutics (NASDAQ:CRSP), GeneDx Holdings (NASDAQ:WGS), WeRide (NASDAQ:WRD)

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?

Photo via WeRide

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?

WeRide Inc. (NASDAQ:WRD) shares rocketed 97.62% after NVIDIA Corporation (NASDAQ:NVDA) disclosed a stake of 1.74 million shares in a 13F filing.
GDS Holdings Limited (NASDAQ:GDS) stock escalated 43.45%, probably after President Trump had reportedly postponed tariffs on packages under $800 from China. Additionally, optimism towards China’s DeepSeek AI model has also lifted stocks recently.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares jumped 42.58% after announcing Merck KGaA (OTC:MKGAF) (OTC:MKKGY) is in advanced discussions to acquire the company.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares increased 40.59%.
Sable Offshore Corp. (NYSE:SOC) stock upped 39.09%.
GeneDx Holdings Corp. (NASDAQ:WGS) shares rose 28.23% after the company announced UltraRapid Whole Genome Sequencing, which will deliver actionable results within 48 hours.
VNET Group, Inc. (NASDAQ:VNET) stock upped 28.22%, probably amid a possible rebound after falling last week due to AI competition concerns related to China’s DeepSeek AI model.
Insperity, Inc. (NYSE:NSP) stock increased 25.99% after the company reported better-than-expected fourth-quarter results.
CRISPR Therapeutics AG (NASDAQ:CRSP) stock grew 25.21% after the company reported better-than-expected fourth-quarter financial results. Several analysts raised the price forecast on the stock.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) stock grew 24.01% after the company reached a settlement agreement with Teva Pharmaceutical (NYSE:TEVA), resolving all patent litigation related to its Auvelity product. Several analysts raised the price forecast on the stock.